Sandoz introduces Symjepi 0.3 mg injection in US market to treat allergic reactions

Sandoz Inc, a Novartis division, announced the US market introduction of Symjepi (epinephrine) 0.3 mg injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.

Symjepi will be rolled out through a phased launch, first in the institutional setting – an established channel where Sandoz Inc. has significant experience and knowledge – followed by introduction into the retail market.

Symjepi 0.3 mg Injection is indicated for the emergency treatment of allergic reactions (Type 1) including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis. Symjepi 0.3 mg Injection is intended for immediate administration in patients who weigh 30 kg (approximately 66 pounds) or more, and who are determined to be at an increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

“The Symjepi device is small in size and fits into the palm of your hand, with the goal of a simple-to-use application and intuitive, user-friendly design,” said Carol Lynch, president of Sandoz Inc. “At Sandoz, we strive to reimagine medicine to offer the best care we can in all we do, and having heard from patients, caregivers and healthcare professionals about their eagerness for a new product, we are proud to be a part of the solution to a critical need in the US.”